New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For APKT;ORCL;SONS;HLF;NUS;BTH;PKT;RMTI;MOBI;PC;RCL;CLX;HUM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
March 23, 2015
09:40 EDTRCLOppenheimer to hold a field trip
Subscribe for More Information
09:07 EDTHUMSelect Medical agrees to acquire Concentra through JV with Welsh Carson
Subscribe for More Information
09:04 EDTHUMHumana to sell Concentra to Select Medical, Welsh Carson for $1.055B in cash
Humana (HUM) has reached a definitive agreement to sell the stock of its wholly-owned subsidiary, Concentra, to MJ Acquisition Corporation, a joint venture between Select Medical Holdings Corporation (SEM), an operator of specialty hospitals and outpatient rehabilitation clinics in the U.S., and Welsh, Carson, Anderson & Stowe XII, L.P., a private equity fund, for approximately $1.055B in cash, subject to customary adjustments. Humana acquired Concentra in December 2010. Subsequently, the assets of certain privately-operated Community Based Outpatient Clinics were transferred into Concentra. Additionally, Humana has divested certain Concentra non-core assets over the past four years. The decision to divest Concentra demonstrates the companyís commitment to its previously announced business portfolio review. Humana will continue performing its review of the alignment and return potential of businesses across the organization to ensure each supports the companyís integrated care delivery strategy and earns the appropriate return on invested capital. The Concentra transaction is anticipated to close during the second quarter of 2015 subject to Hart Scott Rodino regulatory clearance and customary closing conditions. Humana anticipates using the net proceeds from the transaction to advance its strategic growth priorities, to fund additional share repurchases under its existing $2 billion authorization and for general corporate purposes. Goldman, Sachs & Co. is acting as financial advisor to Humana. Fried, Frank, Harris, Shriver & Jacobson LLP is acting as legal advisor to Humana. Concentra reported revenues for the year ended December 31, 2014 were approximately $1B. Humana anticipates the Concentra divestiture will be slightly dilutive to 2015 EPS excluding any one-time gain expected upon the close of the transaction.
09:02 EDTHUMHumana reiterates FY15 EPS view $8.50-$9.00, concensus $8.87
Subscribe for More Information
09:02 EDTHUMHumana to sell Concentra to Select Medical, Welsh Carson for $1.055B in cash
March 20, 2015
16:33 EDTORCLStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information
15:45 EDTHLFHerbalife breaks above top of recent range, levels to watch
Shares have broken out of the top of the recent trading range at $40. This is bullish price behavior. At the current price of $40.79 next resistance is at $42. Support is at $40. It would be bearish for price if the stock resumes trading below the $40 area.
15:38 EDTHLFHerbalife volatility stays elevated on sharp rally
Subscribe for More Information
13:50 EDTHLFPershing Square corrects inaccurate press reports regarding Herbalife
Subscribe for More Information
10:18 EDTORCLOptions with decreasing implied volatility
Options with decreasing implied volatility: NKTR FOLD RUSL RSX ORCL GES CTRP SLXP WSM SPXS
10:00 EDTRCLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:18 EDTHUMLeerink healthcare services analyst holds an analyst/industry conference call
Healthcare Services Analyst Gupte discusses Sustainable Growth Rate (SGR) and the proposed pay-fors and implications For Healthcare Services on an Analyst/Industry conference call to be held on March 20 at 11 am.
06:20 EDTRCLRoyal Caribbean initiated with a Neutral at Wedbush
Target $92.
March 19, 2015
11:02 EDTHLFOptions with increasing implied volatility
Options with increasing implied volatility: HLF RAD NFLX HLSS NOW
10:42 EDTORCLOptions with decreasing implied volatility
Subscribe for More Information
March 18, 2015
16:26 EDTORCLOn The Fly: Closing Wrap
Subscribe for More Information
13:49 EDTHLFHerbalife says 'confident in strong fundamentals of business model'
Subscribe for More Information
12:38 EDTORCLOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday ahead of the conclusion of the Federal Reserve's latest rate setting meeting and the central bank's accompanying announcements. The averages began the session in negative territory and have been range-bound throughout the morning. The Dow was down triple digits once again, making 8 consecutive days that the blue chip index has seen a triple digit move. ECONOMIC EVENTS: In the U.S., the DOE petroleum inventory reports showed a 9.6M barrel rise in crude stocks in the week of March 13, versus expectations for a 4.4M build. The day's big economic news is yet to come, with the Fed's FOMC meeting announcement due at 2:00 pm EDT and Fed Chair Yellen holding a press conference a half hour later. Elsewhere, Prime Minister Benjamin Netanyahu unexpectedly defeated his main challenger in Israelís election and his Likud party appears set to capture more parliament seats. COMPANY NEWS: Shares of FedEx (FDX) slid 2.5% after the shipping giant reported earnings that beat estimates, but revenue that fell short of the consensus forecast, for its third fiscal quarter. FedEx noted that it expects to deliver "record" yearly earnings for the current fiscal year and next fiscal year as well... Oracle (ORCL) shares rose 2.5% after the company's third quarter profits matched expectations and it raised its quarterly dividend 25%. MAJOR MOVERS: Among the notable gainers was Vitesse Semiconductor (VTSS), which jumped 37% after the company agreed to be acquired for $5.28 per share in cash by Microsemi (MSCC). Also higher was Retrophin (RTRX), which rose 28% after the company said it will exercise its right to purchase from Asklepion Pharmaceuticals all worldwide rights, titles, and ownership of Cholbam after the FDA approved the drug for the treatment of pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for patients with peroxisomal disorders. Among the noteworthy losers was Willbros Group (WG), which dropped 55% and was downgraded to Underperform at DA Davidson after announcing its earnings report will be delayed and the company is in potential non-compliance with debt covenants. Also lower following their earnings reports were Nektar Therapeutics (NKTR), which fell 15% after the company's Phase III BEACON metastatic breast cancer study missed its primary endpoint. INDEXES: Near midday, the Dow was down 105.02, or 0.59%, to 17,744.06, the Nasdaq was down 12.45, or 0.25%, to 4,924.99, and the S&P 500 was down 7.69, or 0.37%, to 2,066.59.
10:02 EDTORCLOracle moves higher post-earnings, levels to watch
Shares are up 4.4% to $44.76 at time of writing, just off the high of the day at $44.94. At that price next resistance is at the 52-week high at $46.71. Support is at $44.30, the opening price of the day.
09:33 EDTRCLRoyal Caribbean initiated with a Buy at Buckingham
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use